For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with low PSA levels prior to postprostatectomy radiotherapy who received either short-term or long-term hormone therapy with radiotherapy derived no survival advantage over postprostatectomy radiotherapy alone. Those with higher pre-radiotherapy PSA levels did see some benefit, however, suggesting that adding hormones in this group might be worthwhile.
New AACR President-Elect and Board Members Announced
The members of the American Association for Cancer Research (AACR) have elected Robert H. Vonderheide, MD, DPhil, as the AACR President-elect for 2026–2027. Dr. Vonderheide will become President-Elect on Monday, April 20, during AACR’s Annual Business Meeting of Members at the AACR Annual Meeting 2026 in San Diego. He will assume the Presidency in April 2027 at the AACR Annual Meeting in Orlando.
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges.
Breast Cancer: Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
In a study (PREDICT-DNA) reported in the Journal of Clinical Oncology, Hunter et al found that an ultrasensitive assay for circulating tumor DNA (ctDNA) to detect measurable residual disease after neoadjuvant therapy in patients with breast cancer did not distinguish pathologic complete response (pCR) from no pCR, but did provide important prognostic information.
Forgotten Lessons From South Africa
On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New York Times, opened to the science section, and read aloud: “Cancer Researcher in South Africa Who Falsified Data Is Fired.”
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
Long-Time ASCO Member Philip A. Salem, MD, Honored for Medical Excellence, Leadership, and Compassion
Philip A. Salem, MD On January 29, 2026, Baylor St. Luke’s Medical Center and the Dan L Duncan Comprehensive Cancer Center formally dedicated the Philip A. Salem, MD Conference Center at the O’Quinn Medical Tower. On this occasion, both the governor of Texas and the mayor of the city of...
Association of Body Size and Bladder Cancer Risk
In a study—The Pooling Project of Prospective Studies of Diet and Cancer—reported in the Journal of Clinical Oncology, Milne et al in the National Cancer Institute Cohort Consortium found that increased body size is associated with increased risk of bladder cancer among men, but not among women....
Update to Patient–Clinician Communication Guideline Provides Recommendations on Telehealth, Boundary-Setting
ASCO has updated its guideline on patient–clinician communication, providing recommendations on a range of best practices for explaining treatment options and goals of care, conversing with patients’ support networks, communicating among care team members, and setting boundaries.1 The update to...
Novel Therapies Improve Outcomes Across Hematologic Malignancies
SYED A. ABUTALIB, MD In an effort to help clinicians stay current with rapidly evolving hematology-oncology literature, we are providing these concise, clinically focused summaries of important peer-reviewed studies. These summaries are intended to highlight key findings, study design, and...
Can PFAS Exposure Raise ALL Risk?
Early exposure to per- and polyfluoroalkyl substances (PFAS), a group of widely used compounds known as “forever chemicals,” may be associated with a higher risk of developing acute lymphoblastic leukemia (ALL), according to findings published by Vieira et al in the Journal of Exposure Science...
Cancer Researcher Awarded Sjöberg Prize For Describing Tumors’ Evolution
This year’s Sjöberg Prize of $1 million U.S. dollars was awarded to a British cancer researcher who has provided fundamental knowledge about evolution in tumors. Professor Charles Swanton, FRCP, BSc, PhD, at the Francis Crick Institute in London, described how tumors’ mutations arise and develop....
Melanoma: Gut Microbiome May Help Predict Recurrence After Immunotherapy
Gut bacterial markers may be able to predict recurrence in patients with high-risk melanoma receiving adjuvant immune checkpoint inhibition, according to study findings published in Cell. “Our study identified for the first time gut bacterial types that can serve as markers of increased recurrence ...
